Dearborn Partners LLC Invests $12.64 Million in Zoetis Inc. $ZTS

Dearborn Partners LLC acquired a new stake in shares of Zoetis Inc. (NYSE:ZTS) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 106,920 shares of the company’s stock, valued at approximately $12,639,000.

Several other institutional investors have also recently made changes to their positions in the stock. Ally Financial Inc. purchased a new stake in Zoetis during the 2nd quarter worth about $790,000. Westport Asset Management Inc. purchased a new position in shares of Zoetis during the 2nd quarter valued at $287,000. Flossbach Von Storch SE purchased a new position in shares of Zoetis during the 2nd quarter valued at $302,601,000. Wealthfront Advisers LLC increased its holdings in shares of Zoetis by 80.2% in the second quarter. Wealthfront Advisers LLC now owns 76,113 shares of the company’s stock worth $5,469,000 after purchasing an additional 33,873 shares during the period. Finally, Main Street Financial Solutions LLC bought a new position in shares of Zoetis in the second quarter worth $3,819,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Barclays dropped their price objective on Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 1st. Zacks Research downgraded Zoetis from a “hold” rating to a “strong sell” rating in a research report on Monday, August 10th. Piper Sandler cut their price objective on Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a report on Monday, August 10th. Argus restated a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Finally, BNP Paribas Exane lowered their target price on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 11th. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $109.23.

Zoetis Stock Down 0.8%

Shares of NYSE:ZTS opened at $77.13 on Tuesday. The firm has a market capitalization of $31.87 billion, a PE ratio of 12.71, a price-to-earnings-growth ratio of 1.82 and a beta of 0.73. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. Zoetis Inc. has a 52-week low of $71.00 and a 52-week high of $157.21. The firm has a fifty day moving average of $75.70 and a 200 day moving average of $96.81.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The business had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. During the same quarter last year, the business posted $1.76 earnings per share. The company’s revenue for the quarter was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, research analysts anticipate that Zoetis Inc. will post 6.2 EPS for the current fiscal year.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.